JP2013518687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518687A5 JP2013518687A5 JP2012552160A JP2012552160A JP2013518687A5 JP 2013518687 A5 JP2013518687 A5 JP 2013518687A5 JP 2012552160 A JP2012552160 A JP 2012552160A JP 2012552160 A JP2012552160 A JP 2012552160A JP 2013518687 A5 JP2013518687 A5 JP 2013518687A5
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- blood
- substrate
- serum
- anthrax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000758 substrate Substances 0.000 claims description 62
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 48
- 210000004369 blood Anatomy 0.000 claims description 48
- 239000008280 blood Substances 0.000 claims description 48
- 229920000669 heparin Polymers 0.000 claims description 44
- 229960002897 heparin Drugs 0.000 claims description 44
- 239000011324 bead Substances 0.000 claims description 41
- 241000193738 Bacillus anthracis Species 0.000 claims description 34
- 239000003053 toxin Substances 0.000 claims description 34
- 231100000765 toxin Toxicity 0.000 claims description 34
- 108700012359 toxins Proteins 0.000 claims description 34
- 210000002966 serum Anatomy 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 28
- 244000052769 pathogen Species 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 11
- -1 polyethylene Polymers 0.000 claims description 10
- 239000002156 adsorbate Substances 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 229940065181 bacillus anthracis Drugs 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- 229920001247 Reticulated foam Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 239000002759 woven fabric Substances 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims 8
- 230000001665 lethal effect Effects 0.000 claims 8
- 101710124951 Phospholipase C Proteins 0.000 claims 6
- 101710194807 Protective antigen Proteins 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 3
- 101710197219 Alpha-toxin Proteins 0.000 claims 3
- 239000002776 alpha toxin Substances 0.000 claims 3
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims 3
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920002367 Polyisobutene Polymers 0.000 claims 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 102000019361 Syndecan Human genes 0.000 claims 1
- 108050006774 Syndecan Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 230000003715 interstitial flow Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000002636 mycotoxin Substances 0.000 claims 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 1
- 239000004745 nonwoven fabric Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30282610P | 2010-02-09 | 2010-02-09 | |
| US61/302,826 | 2010-02-09 | ||
| PCT/US2011/024229 WO2011100354A1 (en) | 2010-02-09 | 2011-02-09 | Removal of virulence factors through extracorporeal therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044951A Division JP2015131831A (ja) | 2010-02-09 | 2015-03-06 | 体外治療による毒性因子の除去 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518687A JP2013518687A (ja) | 2013-05-23 |
| JP2013518687A5 true JP2013518687A5 (https=) | 2014-07-17 |
| JP5774607B2 JP5774607B2 (ja) | 2015-09-09 |
Family
ID=43975201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552160A Active JP5774607B2 (ja) | 2010-02-09 | 2011-02-09 | 体外治療による毒性因子の除去 |
| JP2015044951A Pending JP2015131831A (ja) | 2010-02-09 | 2015-03-06 | 体外治療による毒性因子の除去 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044951A Pending JP2015131831A (ja) | 2010-02-09 | 2015-03-06 | 体外治療による毒性因子の除去 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120305482A1 (https=) |
| EP (1) | EP2533828B1 (https=) |
| JP (2) | JP5774607B2 (https=) |
| KR (1) | KR101486879B1 (https=) |
| CN (1) | CN102791307B (https=) |
| AU (1) | AU2011215942B8 (https=) |
| CA (1) | CA2786550C (https=) |
| ES (1) | ES2728122T3 (https=) |
| WO (1) | WO2011100354A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1960016T3 (en) | 2005-12-13 | 2017-01-09 | Exthera Medical Corp | Method for extracorporeal removal by a pathogenic MI-KROBE, an inflammatory cell or inflammatory protein from the blood. |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| EP2509604B1 (en) | 2009-12-01 | 2021-03-17 | ExThera Medical Corporation | Device for removing cytokines from blood with surface immobilized polysaccharides |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| EP2861273B1 (en) | 2012-06-13 | 2017-08-23 | ExThera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
| AU2013282320B2 (en) * | 2012-06-29 | 2017-10-19 | Cytosorbents Corporation | Methods of using polymers |
| MX376935B (es) | 2013-06-24 | 2025-03-07 | Exthera Medical Corp | Sistema de filtración de sangre que contiene substrato recubierto con manosa. |
| CA2928866C (en) * | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
| AU2015250107A1 (en) | 2014-04-24 | 2016-11-17 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
| CA2959975A1 (en) | 2014-09-22 | 2016-03-31 | Exthera Medical Corporation | Wearable hemoperfusion device |
| US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| WO2019070507A1 (en) | 2017-10-05 | 2019-04-11 | Fresenius Medical Care Holdings, Inc. | POLYSULFONE-URETHANE COPOLYMER, MEMBRANES AND INCORPORATING PRODUCTS, AND METHODS OF MAKING AND USING THE SAME |
| EP3735281B1 (en) | 2018-01-05 | 2024-11-27 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
| WO2020231830A1 (en) * | 2019-05-16 | 2020-11-19 | Exthera Medical Corporation | Method for modulating endothelial glycocalyx structure |
| AU2021386427A1 (en) * | 2020-11-30 | 2023-07-20 | Alteco Medical Ab | Device for binding and separation of at least one component from a body fluid |
| HUP2200216A1 (hu) | 2022-06-15 | 2023-12-28 | Captec Medical Kft | Nagy teljesítményû, immun-affinitáson alapuló, extrakorporális patogén csapda |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916352A1 (de) * | 1999-04-12 | 2000-10-19 | Braun Melsungen Ag | Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum |
| US6803183B2 (en) * | 2002-07-18 | 2004-10-12 | Clarigen, Inc. | Method for removing pyrogens from plasma and blood for treatment of septic shock |
| CN101124315A (zh) * | 2003-01-17 | 2008-02-13 | 伊势龙医学股份有限公司 | 利用凝集素亲和性血液透析去除血液中病毒的方法 |
| MX2007003608A (es) * | 2004-09-27 | 2007-08-14 | Technion Res & Dev Foundation | Agentes antimicrobianos novedosos. |
| DK1960016T3 (en) | 2005-12-13 | 2017-01-09 | Exthera Medical Corp | Method for extracorporeal removal by a pathogenic MI-KROBE, an inflammatory cell or inflammatory protein from the blood. |
| AU2008265838A1 (en) * | 2007-06-18 | 2008-12-24 | Exthera Medical Llc | Device and method for restoration of the condition of blood |
-
2011
- 2011-02-09 AU AU2011215942A patent/AU2011215942B8/en active Active
- 2011-02-09 KR KR1020127022418A patent/KR101486879B1/ko active Active
- 2011-02-09 JP JP2012552160A patent/JP5774607B2/ja active Active
- 2011-02-09 ES ES11705110T patent/ES2728122T3/es active Active
- 2011-02-09 WO PCT/US2011/024229 patent/WO2011100354A1/en not_active Ceased
- 2011-02-09 CN CN201180008828.6A patent/CN102791307B/zh active Active
- 2011-02-09 CA CA2786550A patent/CA2786550C/en active Active
- 2011-02-09 US US13/577,529 patent/US20120305482A1/en not_active Abandoned
- 2011-02-09 EP EP11705110.2A patent/EP2533828B1/en active Active
-
2015
- 2015-03-06 JP JP2015044951A patent/JP2015131831A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518687A5 (https=) | ||
| US11844895B2 (en) | Method for removing bacteria from blood using high flow rate | |
| US11123466B2 (en) | Methods for removing cytokines from blood with surface immobilized polysaccharides | |
| EP2735360B1 (en) | Adsorber device combining beads and hollow fiber membranes | |
| CN103221079B (zh) | 新颖的内毒素吸着剂 | |
| KR20230166107A (ko) | 여과 매체 | |
| JP3926573B2 (ja) | フィブリノーゲンおよび／またはフィブリンの濃度を減少させるための吸着剤の製造法、吸着剤、および吸着装置の製造のための吸着剤の使用 | |
| AU2014277852B2 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| JPH05269203A (ja) | 低比重リポ蛋白質を除去した血漿を製造する方法 | |
| HK1230116A1 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| HK1230116B (zh) | 使用固定於表面的多糖从血液中去除细胞因子的方法 | |
| HK1231791B (en) | Method for removing bacteria from blood using high flow rate | |
| HK1231791A1 (en) | Method for removing bacteria from blood using high flow rate | |
| HK1177151B (en) | Method for removing cytokines from blood with surface immobilized polysaccharides |